LevTech aims to extend the lifespan of heart valve replacements without necessitating anticoagulants.
LevTech polymeric heart valves are investigational and are not available for sale.
They are not FDA approved and their clinical safety and efficacy have not been demonstrated.
Novel Materials + Innovative Design + Automated Manufacturing
Proprietary polymeric materials, uniquely synthesized to withstand blood clot formation, calcification, and biodegradation.
Innovative designs optimized through computational modelling to maximize hydrodynamic performance for various patient groups.
Automated manufacturing that enables scalability, product diversity, short production time, and high precision.
Team
Dr. Sina Naficy, CTO
Sina is an experienced polymer engineer holding a PhD in Materials Engineering (2011) as well as a MSc (2004) and a BSc (2001) in Polymer Science and Engineering. He is an adjunct Associate Professor at the University of Sydney.
Dr. David S. Winlaw, Director
David is a cardiothoracic surgical innovator as well as an experienced neonatal surgeon. He is the Division Head of Cardiovascular-Thoracic Surgery and the Co-Executive Director of Heart Center at the Ann & Robert H. Lurie Children's Hospital of Chicago. He also holds Willis J. Potts, MD Founders’ Board Professorship in Surgery and is a Professor of Surgery (Pediatric Cardiovascular-Thoracic Surgery), Willis J. Potts Chair, at Northwestern University Feinberg School of Medicine (IL, USA).
Mr. Nick Northcott, Director
Nick is an experienced management consultant with 20 years’ experience as an Executive Chairman, Managing Director, Consulting Partner, COO and HR Director working with large enterprises (including listed entities), government, private high growth ventures, not for profits and SMEs.
Project has been supported by
